抗病毒治疗对慢性病毒性肝炎患者肝细胞癌风险的影响

StephenW

Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254. [Epub ahead of print]
Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E1, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K.
Author information

1
    First Propaedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Abstract

Hepatocellular carcinoma (HCC) is a major complication of chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Accumulating data suggest that antiviral treatment in both CHB and CHC reduces the incidence of HCC. Evidence is more consistent for interferon-based treatment in both CHB and CHC and for lamivudine in patients with CHB. However, more limited data suggest that other nucleos(t)ide analogues might also reduce the risk of HCC. In contrast, conflicting data have been reported on the effects of direct-acting antivirals on the incidence of HCC.

PMID:
    30179906
DOI:
    10.1097/MEG.0000000000001254

StephenW

Eur J Gastroenterol Hepatol。 2018年9月1日：doi：10.1097 / MEG.0000000000001254。 [提前打印]
抗病毒治疗对慢性病毒性肝炎患者肝细胞癌风险的影响。
Stournaras E1，Neokosmidis G，Stogiannou D，Protopapas A，Tziomalos K.
作者信息

1
    希腊塞萨洛尼基AHEPA医院塞萨洛尼基亚里士多德大学医学院内科第一医学科。

抽象

肝细胞癌（HCC）是慢性乙型肝炎（CHB）和慢性丙型肝炎（CHC）的主要并发症。累积数据表明，CHB和CHC的抗病毒治疗均可降低HCC的发病率。基于干扰素的CHB和CHC治疗以及CHB患者拉米夫定治疗的证据更为一致。然而，更有限的数据表明其他核苷（酸）类似物也可能降低HCC的风险。相比之下，有关直接作用抗病毒药物对HCC发病率的影响的报道数据相互矛盾。

结论：
    30179906
DOI：
    10.1097 / MEG.0000000000001254